An Open-label Study to Assess the Efficacy and Safety of Alipogene Tiparvovec (AMT-011), Human LPL [S447X], Expressed by an Adeno-Associated Viral Vector After Intramuscular Administration in LPL-deficient Adult Subjects.

Trial Profile

An Open-label Study to Assess the Efficacy and Safety of Alipogene Tiparvovec (AMT-011), Human LPL [S447X], Expressed by an Adeno-Associated Viral Vector After Intramuscular Administration in LPL-deficient Adult Subjects.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 02 Nov 2015

At a glance

  • Drugs Alipogene tiparvovec; Ciclosporin; Methylprednisolone; Mycophenolate mofetil
  • Indications Hyperlipoproteinaemia type I; Hypertriglyceridaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Amsterdam Molecular Therapeutics
  • Most Recent Events

    • 28 Sep 2011 Actual initiation date (February 2009) added as reported by ClinicalTrials.gov.
    • 28 Sep 2011 Actual end date (April 2011) added as reported by ClinicalTrials.gov.
    • 28 Sep 2011 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top